Literature DB >> 11454600

Cardiac-directed overexpression of wild-type alpha1B-adrenergic receptor induces dilated cardiomyopathy.

I Lemire1, A Ducharme, J C Tardif, F Poulin, L R Jones, B G Allen, T E Hébert, H Rindt.   

Abstract

Using transgenesis as a paradigm, we show here that alpha1-adrenergic receptors (alpha1AR) play an important role in cardiac homeostasis. Cardiomyocyte-specific overexpression of the alpha(1B)AR subtype resulted in the development of dilated cardiomyopathy and death at ~9 mo of age with typical signs of heart failure. Histological analyses showed the enlargement of all four cardiac chambers and cardiomyocyte disarray in the failing hearts. Transgenic animals showed increased left ventricular areas, as assessed by echocardiography. In addition, a progressive decrease in left ventricular systolic function was revealed. The abundance and activity of sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2) were reduced, and the ratio of phospholamban to SERCA2 was increased. alpha-Myosin heavy chain (MHC) mRNA was less abundant in older transgenic ventricles, whereas beta-MHC was induced in the failing hearts. Titin mRNA abundance was decreased at 9 mo, whereas atrial natriuretic factor mRNA was elevated at all times. This model mimics structural and functional features of idiopathic dilated cardiomyopathy. The results of this study suggest that chronic alpha1AR activity is deleterious for cardiac function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454600     DOI: 10.1152/ajpheart.2001.281.2.H931

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  13 in total

Review 1.  Adrenoceptor regulation of the mechanistic target of rapamycin in muscle and adipose tissue.

Authors:  Ling Yeong Chia; Bronwyn A Evans; Saori Mukaida; Tore Bengtsson; Dana S Hutchinson; Masaaki Sato
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

Review 2.  Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure.

Authors:  Brian C Jensen; Timothy D O'Connell; Paul C Simpson
Journal:  J Mol Cell Cardiol       Date:  2010-11-28       Impact factor: 5.000

Review 3.  Cardiac and neuroprotection regulated by α(1)-adrenergic receptor subtypes.

Authors:  Dianne M Perez; Van A Doze
Journal:  J Recept Signal Transduct Res       Date:  2011-02-21       Impact factor: 2.092

Review 4.  Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances.

Authors:  Kelley P Anderson
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-01       Impact factor: 1.468

Review 5.  Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance.

Authors:  Timothy D O'Connell; Brian C Jensen; Anthony J Baker; Paul C Simpson
Journal:  Pharmacol Rev       Date:  2013-12-24       Impact factor: 25.468

6.  α₁A-adrenergic receptors regulate cardiac hypertrophy in vivo through interleukin-6 secretion.

Authors:  Robert S Papay; Ting Shi; Michael T Piascik; Sathyamangla V Naga Prasad; Dianne M Perez
Journal:  Mol Pharmacol       Date:  2013-02-12       Impact factor: 4.436

Review 7.  Alpha-1-adrenergic receptors in heart failure: the adaptive arm of the cardiac response to chronic catecholamine stimulation.

Authors:  Brian C Jensen; Timothy D OʼConnell; Paul C Simpson
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

8.  {alpha}1-Adrenergic receptor subtypes in nonfailing and failing human myocardium.

Authors:  Brian C Jensen; Philip M Swigart; Teresa De Marco; Charles Hoopes; Paul C Simpson
Journal:  Circ Heart Fail       Date:  2009-08-06       Impact factor: 8.790

Review 9.  Adrenergic signaling in heart failure: a balance of toxic and protective effects.

Authors:  Anthony J Baker
Journal:  Pflugers Arch       Date:  2014-03-14       Impact factor: 3.657

Review 10.  Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.

Authors:  Dianne M Perez
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.